On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Pakistan and Afghanistan reported wild poliovirus type 1 cases, and Chad, Niger, and Niger reported circulating ...

Regarding Rwanda's latest two cases, the World Health Organization (WHO) said in an outbreak update today that one of the ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session.

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 15,078.84 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...